Cookson Peirce & Co. Inc. Grows Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Cookson Peirce & Co. Inc. increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 61.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,081 shares of the biopharmaceutical company’s stock after buying an additional 10,718 shares during the period. Cookson Peirce & Co. Inc.’s holdings in TG Therapeutics were worth $845,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. increased its stake in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 371 shares during the period. Smartleaf Asset Management LLC increased its stake in TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 1,594 shares during the period. Jones Financial Companies Lllp increased its stake in TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 1,737 shares during the period. Synergy Asset Management LLC purchased a new stake in TG Therapeutics during the 4th quarter worth $75,000. Finally, GAMMA Investing LLC increased its stake in TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 2,171 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Insider Activity

In other news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 10.50% of the company’s stock.

TG Therapeutics Trading Down 1.4 %

NASDAQ TGTX opened at $35.11 on Thursday. TG Therapeutics, Inc. has a one year low of $12.93 and a one year high of $36.94. The company has a 50-day simple moving average of $30.86 and a 200-day simple moving average of $28.33. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market capitalization of $5.47 billion, a PE ratio of -351.06 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. On average, equities analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analysts Set New Price Targets

TGTX has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday. Finally, StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.